Cutaneous leishmaniasis in a patient receiving infliximab

Abstract

Leishmaniasis is endemic in the Mediterranean region, and the prevalence of latent infection in this area is high. Treatment with tumour necrosis factor (TNF) antagonists represents a major breakthrough in the treatment of several inflammatory diseases, including psoriasis. Reports describing opportunistic leishmaniasis in European patients treated with TNF-α antagonist drugs are rapidly accumulating. We describe a case of cutaneous leishmaniasis in a patient treated with infliximab and corticosteroids.

Keywords::

• Leishmania
• cutaneous leishmaniasis
• tumour necrosis factor antagonists
• infliximab

Declaration of interest: The authors declare no conflict of interest.